Credo Diagnostics Biomedical is finalizing a rapid point-of-care molecular test for the detection of novel Coronavirus COVID-19 in 20 minutes
To date, the novel Coronavirus has killed more than 2,0 […]
To date, the novel Coronavirus has killed more than 2,0 […]
Focusing on research and development of revolutionary diagnostic technologies since 2011, Credo Diagnostics develops, manufactures, and commercializes accurate, rapid, and affordable molecular diagnostic solutions at the Point-Of-Care testing.
© 2023 | Credo Diagnostics Biomedical Pte. Ltd.